IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?

It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activit...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Fernanda Costa Brandão Berti [verfasserIn] Karen Brajão de Oliveira [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity

Übergeordnetes Werk:	In: AIMS Allergy and Immunology - American Institute of Mathematical Sciences, 2018, 2(2018), 2, Seite 88-97
Übergeordnetes Werk:	volume:2 ; year:2018 ; number:2 ; pages:88-97

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3934/Allergy.2018.2.88

Katalog-ID:	DOAJ079366171

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ079366171
003	DE-627
005	20230501174156.0
007	cr uuu---uuuuu
008	230307s2018 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3934/Allergy.2018.2.88 \|2 doi
035			\|a (DE-627)DOAJ079366171
035			\|a (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC581-607
100	0		\|a Fernanda Costa Brandão Berti \|e verfasserin \|4 aut
245	1	0	\|a IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.
650		4	\|a IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity
653		0	\|a Immunologic diseases. Allergy
700	0		\|a Karen Brajão de Oliveira \|e verfasserin \|4 aut
773	0	8	\|i In \|t AIMS Allergy and Immunology \|d American Institute of Mathematical Sciences, 2018 \|g 2(2018), 2, Seite 88-97 \|w (DE-627)1676294031 \|x 2575615X \|7 nnns
773	1	8	\|g volume:2 \|g year:2018 \|g number:2 \|g pages:88-97
856	4	0	\|u https://doi.org/10.3934/Allergy.2018.2.88 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 \|z kostenfrei
856	4	0	\|u http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2575-615X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 2 \|j 2018 \|e 2 \|h 88-97

Indexfelder

author_variant	f c b b fcbb k b d o kbdo
matchkey_str	article:2575615X:2018----::l0nacrutcasclmuoupesvfcooasa
hierarchy_sort_str	2018
callnumber-subject-code	RC
publishDate	2018
allfields	10.3934/Allergy.2018.2.88 doi (DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66 DE-627 ger DE-627 rakwb eng RC581-607 Fernanda Costa Brandão Berti verfasserin aut IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one. IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy Karen Brajão de Oliveira verfasserin aut In AIMS Allergy and Immunology American Institute of Mathematical Sciences, 2018 2(2018), 2, Seite 88-97 (DE-627)1676294031 2575615X nnns volume:2 year:2018 number:2 pages:88-97 https://doi.org/10.3934/Allergy.2018.2.88 kostenfrei https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 kostenfrei http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html kostenfrei https://doaj.org/toc/2575-615X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2018 2 88-97
spelling	10.3934/Allergy.2018.2.88 doi (DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66 DE-627 ger DE-627 rakwb eng RC581-607 Fernanda Costa Brandão Berti verfasserin aut IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one. IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy Karen Brajão de Oliveira verfasserin aut In AIMS Allergy and Immunology American Institute of Mathematical Sciences, 2018 2(2018), 2, Seite 88-97 (DE-627)1676294031 2575615X nnns volume:2 year:2018 number:2 pages:88-97 https://doi.org/10.3934/Allergy.2018.2.88 kostenfrei https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 kostenfrei http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html kostenfrei https://doaj.org/toc/2575-615X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2018 2 88-97
allfields_unstemmed	10.3934/Allergy.2018.2.88 doi (DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66 DE-627 ger DE-627 rakwb eng RC581-607 Fernanda Costa Brandão Berti verfasserin aut IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one. IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy Karen Brajão de Oliveira verfasserin aut In AIMS Allergy and Immunology American Institute of Mathematical Sciences, 2018 2(2018), 2, Seite 88-97 (DE-627)1676294031 2575615X nnns volume:2 year:2018 number:2 pages:88-97 https://doi.org/10.3934/Allergy.2018.2.88 kostenfrei https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 kostenfrei http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html kostenfrei https://doaj.org/toc/2575-615X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2018 2 88-97
allfieldsGer	10.3934/Allergy.2018.2.88 doi (DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66 DE-627 ger DE-627 rakwb eng RC581-607 Fernanda Costa Brandão Berti verfasserin aut IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one. IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy Karen Brajão de Oliveira verfasserin aut In AIMS Allergy and Immunology American Institute of Mathematical Sciences, 2018 2(2018), 2, Seite 88-97 (DE-627)1676294031 2575615X nnns volume:2 year:2018 number:2 pages:88-97 https://doi.org/10.3934/Allergy.2018.2.88 kostenfrei https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 kostenfrei http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html kostenfrei https://doaj.org/toc/2575-615X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2018 2 88-97
allfieldsSound	10.3934/Allergy.2018.2.88 doi (DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66 DE-627 ger DE-627 rakwb eng RC581-607 Fernanda Costa Brandão Berti verfasserin aut IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one. IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy Karen Brajão de Oliveira verfasserin aut In AIMS Allergy and Immunology American Institute of Mathematical Sciences, 2018 2(2018), 2, Seite 88-97 (DE-627)1676294031 2575615X nnns volume:2 year:2018 number:2 pages:88-97 https://doi.org/10.3934/Allergy.2018.2.88 kostenfrei https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 kostenfrei http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html kostenfrei https://doaj.org/toc/2575-615X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2 2018 2 88-97
language	English
source	In AIMS Allergy and Immunology 2(2018), 2, Seite 88-97 volume:2 year:2018 number:2 pages:88-97
sourceStr	In AIMS Allergy and Immunology 2(2018), 2, Seite 88-97 volume:2 year:2018 number:2 pages:88-97
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity Immunologic diseases. Allergy
isfreeaccess_bool	true
container_title	AIMS Allergy and Immunology
authorswithroles_txt_mv	Fernanda Costa Brandão Berti @@aut@@ Karen Brajão de Oliveira @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	1676294031
id	DOAJ079366171
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079366171</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501174156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3934/Allergy.2018.2.88</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079366171</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fernanda Costa Brandão Berti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karen Brajão de Oliveira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">AIMS Allergy and Immunology</subfield><subfield code="d">American Institute of Mathematical Sciences, 2018</subfield><subfield code="g">2(2018), 2, Seite 88-97</subfield><subfield code="w">(DE-627)1676294031</subfield><subfield code="x">2575615X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:88-97</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3934/Allergy.2018.2.88</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2575-615X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">88-97</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Fernanda Costa Brandão Berti
spellingShingle	Fernanda Costa Brandão Berti misc RC581-607 misc IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity misc Immunologic diseases. Allergy IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
authorStr	Fernanda Costa Brandão Berti
ppnlink_with_tag_str_mv	@@773@@(DE-627)1676294031
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC581-607
illustrated	Not Illustrated
issn	2575615X
topic_title	RC581-607 IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one? IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity
topic	misc RC581-607 misc IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity misc Immunologic diseases. Allergy
topic_unstemmed	misc RC581-607 misc IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity misc Immunologic diseases. Allergy
topic_browse	misc RC581-607 misc IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity misc Immunologic diseases. Allergy
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	AIMS Allergy and Immunology
hierarchy_parent_id	1676294031
hierarchy_top_title	AIMS Allergy and Immunology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1676294031
title	IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
ctrlnum	(DE-627)DOAJ079366171 (DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66
title_full	IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
author_sort	Fernanda Costa Brandão Berti
journal	AIMS Allergy and Immunology
journalStr	AIMS Allergy and Immunology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	88
author_browse	Fernanda Costa Brandão Berti Karen Brajão de Oliveira
container_volume	2
class	RC581-607
format_se	Elektronische Aufsätze
author-letter	Fernanda Costa Brandão Berti
doi_str_mv	10.3934/Allergy.2018.2.88
author2-role	verfasserin
title_sort	il-10 in cancer: just a classical immunosuppressive factor or also an immunostimulating one?
callnumber	RC581-607
title_auth	IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
abstract	It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.
abstractGer	It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.
abstract_unstemmed	It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?
url	https://doi.org/10.3934/Allergy.2018.2.88 https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66 http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html https://doaj.org/toc/2575-615X
remote_bool	true
author2	Karen Brajão de Oliveira
author2Str	Karen Brajão de Oliveira
ppnlink	1676294031
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3934/Allergy.2018.2.88
callnumber-a	RC581-607
up_date	2024-07-03T23:06:40.711Z
_version_	1803601052394586112
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ079366171</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501174156.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230307s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3934/Allergy.2018.2.88</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ079366171</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a661983724049f2bf423c3a5cda9b66</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC581-607</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Fernanda Costa Brandão Berti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It is generally well-accepted and established the IL-10-mediated protumor function in cancer, based on its immunosuppressive properties. However, new evidences from <em<in vitro</em< and <em<in vivo</em< murine models have emerged showing a potential immunostimulating activity of this cytokine, which may sustain IL-10-mediated antitumor function in cancer, hence favoring tumor regression. Here, we attempt to clarify IL-10’s role in cancer, by conducting a literature review of previously published studies, presenting information about IL-10 immunosuppressive and/or immunostimulating properties. Different and contradictory IL-10 effects leading to tumor growth (e.g., suppression of pro-inflammatory cytokines or inhibition of immune response recognition steps) or tumor regression (e.g., stimulation of cytotoxic and cytolytic activities of immune cells or inhibition of angiogenic factors) were found in distinct scenarios, hindering the establishment of a general role for IL-10 in cancer. Such definition is still a challenge, maybe due to a lack of sufficient information to support it, or perhaps based on the fact that IL-10 role in distinct cancer contexts may vary, switching from a classical immunosuppressive factor to an immunostimulating one.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IL-10\| cancer\| immunosuppression\| immunostimulation\| protumor activity\| antitumor activity</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Immunologic diseases. Allergy</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Karen Brajão de Oliveira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">AIMS Allergy and Immunology</subfield><subfield code="d">American Institute of Mathematical Sciences, 2018</subfield><subfield code="g">2(2018), 2, Seite 88-97</subfield><subfield code="w">(DE-627)1676294031</subfield><subfield code="x">2575615X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:2</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:88-97</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3934/Allergy.2018.2.88</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a661983724049f2bf423c3a5cda9b66</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.aimspress.com/article/10.3934/Allergy.2018.2.88/fulltext.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2575-615X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">2</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">88-97</subfield></datafield></record></collection>
score	7.402815

Nicht das Richtige dabei?

Schreiben Sie uns!

IL-10 in cancer: Just a classical immunosuppressive factor or also an immunostimulating one?

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?